Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Opioid Variations and Effects: Recovery Coach OUD Medications and Evidence-based Therapy (OVERCOME2)

26. oktober 2026 oppdatert av: Prisma Health-Upstate

An Integrated Intervention Involving Recovery Coaching and Cognitive Behavioral Therapy for Opioid Use Disorder

The Overcome II study is a randomized controlled trial among adults receiving sublingual buprenorphine to help prevent or reduce illicit drug use. The study outcomes will be compared between three treatment arms: (1) sublingual buprenorphine only, which is the standard-of-treatment (2) sublingual buprenorphine with a computer-based cognitive behavior therapy for substance use disorders (CBT4CBT), (3) sublingual buprenorphine with CBT4CBT and peer recovery coaching. The primary outcome of interest is the reduction in the proportion of positive results for saliva toxicology screenings for any drug during the 8-week treatment period. Study participants will also be assessed for the outcomes of retention to standard-of-treatment and illicit drug use at 1-, 3-, and 6-months follow-ups after the end of treatment.

Studieoversikt

Detaljert beskrivelse

Buprenorphine has proven to be an effective pharmacologic strategy for treating OUD. However, buprenorphine is unlikely to give greater overall protection because of the shorter duration of treatment. There is a need for studies on interventions that could increase retention to buprenorphine, especially among those with ongoing illicit substance and polysubstance use.

Using a randomized controlled trial study design, the Overcome II study aims to investigate the incremental benefit in terms of reduction in illicit drug use and retention in standard of treatment due to providing the peer recovery coach and/or CBT4CBT interventions as a compliment to standard-of-treatment among persons receiving medication for opioid use. The study outcomes will be compared between three treatment arms: (1) sublingual buprenorphine only, which is the standard-of-treatment (2) sublingual buprenorphine with CBT4CBT, (3) sublingual buprenorphine with CBT4CBT and peer recovery coaching. The primary outcome of interest is reduction in the proportion of positive results for saliva toxicology screenings for any drug during the 8-week treatment period. Study participants will also be assessed for the outcomes of retention to standard-of-treatment and illicit drug use at 1-, 3-, and 6-months follow-ups after the end of treatment. The institutional review board at Prisma Health will provide the oversight for the ethical conduct of the study. Potential participants at Prisma Health will be screened for eligibility, will undergo the informed consent procedure, and eligible persons who consent to participation will be recruited into the study.

The participants will be randomized of one of the three treatment arms in a 1:1:1 ratio. The study will aim to recruit 30 participants per treatment arm. Study procedures will be conducted both virtually and at research facilities of the Prisma Health Addiction Medicine Center, in Greenville, SC. Participants will attend the research visits once a week during the first eight weeks (sessions 1 to 8), and 1-, 3-, and 6- months after the end of treatment.

Studietype

Intervensjonell

Registrering (Faktiske)

92

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • South Carolina
      • Greenville, South Carolina, Forente stater, 29605
        • Greenville Health System

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Adults (≥18 years of age);
  2. DSM-V diagnosis of OUD, confirmed via electronic medical record review;
  3. Currently receiving SL buprenorphine/ naloxone and/or buprenorphine HCL;
  4. Initiated SL buprenorphine within the last 30 days;
  5. Willing to accept a random assignment to either treatment arm:
  6. Adequate computer skills

Exclusion Criteria:

  1. Severe medical or psychiatric disability that could impair the ability to perform study related activities (determined by the clinician);
  2. Pregnancy, planning conception, or breast-feeding for female participants;
  3. Inability to independently read and/or comprehend the consent form or other study materials;
  4. Inability to read/speak English (inability to independently read and comprehend the consent form or other study materials);
  5. Current suicidal ideation based on the Patient Health Questionnaire-9
  6. Have taken or received any prescribed buprenorphine product within 30 days prior to the current treatment episode.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Standard of care

Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.

Participants in the standard of care condition will receive the standard treatment at the recovery program, which consists of weekly, bi-weekly or monthly visits (at the discretion of the provider) in-person or virtually. This condition will be matched with the other conditions in terms of the number of research visits.

Eksperimentell: Standard of care + CBT4CBT

This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.

This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.

Andre navn:
  • CBT4CBT-buprenorfin
Eksperimentell: Standard of care + CBT4CBT+ RC

This condition will integrate the standard of care, CBT4CBT, and recovery coaching services with Assertive Community Engagement (ACE) model interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.

This condition will integrate the standard of care and CBT4CBT interventions. The CBT4CBT is an 8-session (module) system for teaching with one module on the basics of buprenorphine and the other modules on the seven CBT core skills tailored around issues related to buprenorphine and OUD and other SUDs: (1) Introduction to functional analysis of substance use; (2) strategies for recognizing and coping with craving; (3) refusal skills and assertiveness; (4) training in problem-solving skills; (5) strategies for recognizing and changing thoughts; (6) decision-making skills; (7) how to use CBT skills to reduce HIV/ HCV risk. Each module takes 30 minutes to complete and has a format, which includes on-screen narration, animation, quizzes, and interactive exercises to teach and model effective use of skills. Modules end with a practice exercise.

Andre navn:
  • CBT4CBT-buprenorfin

Peer recovery coaching services involve a form of nonclinical, peer support aimed at helping individuals with substance use disorders to achieve and maintain recovery. Recovery coaches are individuals with experience with substance use and successful recovery. In addition to their lived experience, recovery coaches obtain formal training on substance use coaching and receive ongoing supervision. The recovery coaches use an assertive engagement approach to provide holistic, person-centered, and strength-based support.

Andre navn:
  • Recovery coaching

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Drug Use
Tidsramme: 8 weeks

The percentage of of saliva toxicology screens positive for all drugs during the 8 initial study weeks

8 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Retained to Buprenorphine at 3 Months
Tidsramme: 3 months post-treatment follow up at 20 weeks

Retention to buprenorphine

3 months post-treatment follow up at 20 weeks
Number of Participants Retained to Buprenorphine at 6 Months
Tidsramme: 3 months post-treatment follow up at 32 weeks

Retention to buprenorphine

3 months post-treatment follow up at 32 weeks
Drug Use
Tidsramme: Percentage of positive saliva toxicology screens at 12 week mark

The percentage of saliva toxicology screens positive for all drugs at 1 month follow-up

Percentage of positive saliva toxicology screens at 12 week mark
Drug Use
Tidsramme: Percentage of positive saliva toxicology screens at 20 week mark

The percentage of saliva toxicology screens positive for all drugs at 3 month follow-up

Percentage of positive saliva toxicology screens at 20 week mark
Drug Use
Tidsramme: Percentage of positive saliva toxicology screens at 32 week mark

The percentage of saliva toxicology screens positive for all drugs at 6 month follow-up

Percentage of positive saliva toxicology screens at 32 week mark
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at during first 8 weeks of study participation

The percentage of saliva toxicology screens positive for opioids during the 8 initial study weeks

Percentage of opioid positive saliva toxicology screens at during first 8 weeks of study participation
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at 12 week mark

The percentage of saliva toxicology screens positive for opioids at 1 month follow-up

Percentage of opioid positive saliva toxicology screens at 12 week mark
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at 20 week mark

The percentage of saliva toxicology screens positive for opioids at 3- month follow-up

Percentage of opioid positive saliva toxicology screens at 20 week mark
Opioid Use
Tidsramme: Percentage of opioid positive saliva toxicology screens at 32 week mark

The percentage of saliva toxicology screens positive for opioids at 6- month follow-up

Percentage of opioid positive saliva toxicology screens at 32 week mark
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 8 week mark

Self-report drug use in the past 30 days

Self-reported drug use in the last 30 days, captured at 8 week mark
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 12 week mark

Self-report drug use in the past 30 days

Self-reported drug use in the last 30 days, captured at 12 week mark
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 20 week mark

Self-report drug use in the past 30 days

Self-reported drug use in the last 30 days, captured at 20 week mark
Positive Self-report Drug Use
Tidsramme: Self-reported drug use in the last 30 days, captured at 32 week mark

Self-report drug use in the past 30 days

Self-reported drug use in the last 30 days, captured at 32 week mark

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Alain H Litwin, MD, Prisma Health

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. oktober 2023

Primær fullføring (Faktiske)

5. juni 2025

Studiet fullført (Faktiske)

6. desember 2025

Datoer for studieregistrering

Først innsendt

31. august 2023

Først innsendt som oppfylte QC-kriteriene

20. oktober 2023

Først lagt ut (Faktiske)

26. oktober 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. oktober 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 1930664-6
  • R34DA057662 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere